SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($2.46), $0.04 better than the analyst estimate of ($2.50). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $2.41 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.